Last reviewed · How we verify
Selegiline Transdermal System — Competitive Intelligence Brief
marketed
Small molecule
Live · refreshed every 30 min
Target snapshot
Selegiline Transdermal System (Selegiline Transdermal System) — Somerset Pharmaceuticals.
Comparator set
| Drug | Generic | Sponsor | Phase | Class | Target | Approval / PDUFA |
|---|---|---|---|---|---|---|
| Selegiline Transdermal System TARGET | Selegiline Transdermal System | Somerset Pharmaceuticals | marketed |
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Sponsor landscape
Subscribe to ongoing alerts
Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:
- Selegiline Transdermal System CI watch — RSS
- Selegiline Transdermal System CI watch — Atom
- Selegiline Transdermal System CI watch — JSON
- Selegiline Transdermal System alone — RSS
Cite this brief
Drug Landscape (2026). Selegiline Transdermal System — Competitive Intelligence Brief. https://druglandscape.com/ci/selegiline-transdermal-system. Accessed 2026-05-16.
Build your own brief
Pick any drug + add comparators:
https://druglandscape.com/ci/{slug}— auto-detected competitorshttps://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3— explicit comparators- Brand names auto-resolve:
/ci/keytruda→ 301 →/ci/pembrolizumab